Moderna Adjusts 2025 Revenue Expectations, Shares Fall By Investing.com

Investing.com — Modern (NASDAQ:) has revised its revenue forecast for 2025, resulting in a drop in the company’s share price.

The biotech company now expects sales in 2025 to fall between $1.5 billion and $2.5 billion.

This prediction, with a midpoint of $2 billion, falls short of the previous consensus forecast of $2.92 billion.

In response to the revised forecast, Moderna has announced that it will step up its cost-saving measures.

By the end of 2025, the company aims to have approximately $6 billion in cash. This decision to revise its revenue forecast and increase cost-cutting initiatives has led to a drop in Moderna’s shares.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.